COMPANY
Sanaria Inc.
Funding and NIH signals
- NIH award NIH awarded $1M (SBIR commercialization 1SB1AI195021-01, new, notice Sep 18, 2026); 2 NIH awards totaling $2M in the last 12 months. NIH RePORTER 1SB1AI195021-01 (Sep 18, 2026)
Evidence (2 events)
- Sep 18, 2026 · NIH RePORTER 1SB1AI195021-01
Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 1SB1AI195021-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.; Organization type: Domestic For-Profits - Sep 17, 2026 · NIH RePORTER 5U44AI124867-08
Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 5U44AI124867-08; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites; Organization type: Domestic For-Profits
- Sep 18, 2026 · NIH RePORTER 1SB1AI195021-01
Timeline
- Trial start Phase 1: Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso source ↗
- Grant Government grant — SBIR: $1M (annual award, as published), announced Sep 18, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — SBIR: $1M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Trial start Phase 2: PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali source ↗
- Trial start Phase 2: Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults source ↗
- Trial start Phase 1: Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults source ↗
- Grant Government grant — SBIR: $1M (annual award, as published), announced Sep 10, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — NIH U01: $945,493 (annual award, as published), announced Jul 18, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — NIH U01: $1.01M (annual award, as published), announced Jul 18, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — SBIR: $995,072 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — SBIR: $999,150 (annual award, as published), announced Jun 27, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Trial start Phase 1: Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso source ↗
- Trial start 1: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI source ↗
- Trial start Phase 2: Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria source ↗
- Trial start Phase 2: PfSPZ Vaccine Trial in Malian Children source ↗
- Trial start Phase 1: Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults source ↗
- Trial start Phase 1: Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea source ↗
- Trial start Phase 2: Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children source ↗
- Trial start Phase 1: Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults source ↗
- Trial start Phase 1: Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers source ↗
- Trial start Phase 1: Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea. source ↗
- Trial start Phase 1: Sequential Optimization of Dose and Schedule of PfSPZ Vaccine source ↗
- Trial start Phase 1/Phase 2: Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya source ↗
- Trial start Phase 2: PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults source ↗
- Trial start Phase 1: Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants source ↗
Upcoming milestones
- 2027-02 (ESTIMATED) · Phase 2 · Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults · NCT07385287
- 2027-12 (ESTIMATED) · Phase 1 · Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso · NCT07730177
- Jul 15, 2028 (ESTIMATED) · Phase 2 · PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali · NCT07675785
Funding
- Government grant — SBIR: $1M (annual award, as published), announced Sep 18, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $1M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $1M (annual award, as published), announced Sep 10, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — NIH U01: $945,493 (annual award, as published), announced Jul 18, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — NIH U01: $1.01M (annual award, as published), announced Jul 18, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $995,072 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $999,150 (annual award, as published), announced Jun 27, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Clinical trials (lead sponsor) 29
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07730177 | Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso | Phase 1 | Not yet recruiting | 2027-03 | 2027-12 (estimated) |
| NCT07675785 | PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali | Phase 2 | Recruiting | Jul 20, 2026 | Jul 15, 2028 (estimated) |
| NCT06862453 | Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults | Phase 1 | Recruiting | Mar 12, 2026 | Sep 30, 2026 (estimated) |
| NCT07385287 | Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults | Phase 2 | Recruiting | May 4, 2026 | 2027-02 (estimated) |
| NCT03503058 | Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria | Phase 2 | Completed | May 7, 2022 | Feb 27, 2024 (actual) |
| NCT06652737 | Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso | Phase 1 | Completed | Mar 4, 2025 | Feb 18, 2026 (actual) |
| NCT05604521 | A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI | 1 | Terminated | Dec 6, 2022 | Sep 5, 2023 (actual) |
| NCT04940130 | PfSPZ Vaccine Trial in Malian Children | Phase 2 | Completed | Apr 1, 2022 | Dec 10, 2022 (actual) |
| NCT04966871 | Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults | Phase 1 | Completed | Sep 27, 2021 | Jun 21, 2022 (actual) |
| NCT03521973 | Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children | Phase 2 | Completed | Jun 14, 2018 | May 18, 2021 (actual) |
| NCT03590340 | Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea | Phase 1 | Completed | Jul 30, 2018 | Mar 12, 2019 (actual) |
| NCT02687373 | Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya | Phase 1/Phase 2 | Completed | Jul 21, 2016 | 2018-08 (actual) |
| NCT03420053 | Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults | Phase 1 | Completed | Feb 7, 2018 | Aug 25, 2018 (actual) |
| NCT03163121 | Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers | Phase 1 | Completed | May 12, 2017 | Oct 25, 2018 (actual) |
| NCT02704533 | Sequential Optimization of Dose and Schedule of PfSPZ Vaccine | Phase 1 | Completed | Aug 29, 2016 | Oct 19, 2018 (actual) |
| NCT02601716 | PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults | Phase 2 | Completed | 2016-01 | 2017-09 (actual) |
| NCT02613520 | Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants | Phase 1 | Completed | 2015-12 | 2017-02 (actual) |
| NCT02859350 | Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea. | Phase 1 | Completed | 2016-11 | 2017-12 (actual) |
| NCT02215707 | A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses | Phase 1 | Completed | 2014-06 | 2015-04 (actual) |
| NCT01728701 | Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis | Phase 1 | Completed | 2012-09 | 2013-12 (actual) |
| NCT02115516 | Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis | Phase 1 | Completed | 2014-04 | 2015-12 (actual) |
| NCT02132299 | Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults | Phase 1 | Completed | 2014-04 | 2015-07 (actual) |
| NCT01624961 | Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults | Phase 1 | Completed | 2012-06 | 2012-10 (actual) |
| NCT01771848 | Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults | Phase 1 | Completed | 2012-12 | 2013-05 (actual) |
| NCT02418962 | Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults | Phase 1 | Completed | 2015-03 | 2015-09 (actual) |
| NCT02237586 | Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge | Phase 1 | Completed | 2014-07 | 2014-09 (actual) |
| NCT01086917 | Experimental Human Malaria Infection by PfSPZ | Phase 1 | Completed | 2010-08 | 2011-02 (actual) |
| NCT01001650 | Clinical Trial of the PfSPZ Vaccine | Phase 1 | Completed | 2009-04 | 2010-07 (actual) |
| NCT01540903 | Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults | Phase 1 | Completed | 2012-02 | 2012-09 (actual) |
NIH awards 50
- NIH award 5R43AI179439-02 FY2024: $277,702 awarded for that fiscal year; activity R43 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Modularizing manufacture of PfSPZ vaccines: o source ↗
- NIH award 2U44AI124867-06 FY2024: $1,000,000 awarded for that fiscal year; activity U44 (SBIR); PI CHAKRAVARTY, SUMANA; recipient as written: SANARIA, INC., ROCKVILLE, MD. Manufacture of aseptic, purified, cryopreser source ↗
- NIH award 5R44AI125009-06 FY2024: $968,360 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. A glycolipid adjuvant to promote dose sparing source ↗
- NIH award 5SB1AI174403-02 FY2024: $999,345 awarded for that fiscal year; activity SB1 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Progressing PfSPZ vaccines for malaria to lic source ↗
- NIH award 5U01AI155356-04 FY2024: $1,083,506 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. Expanding the breadth, magnitude, and durab source ↗
- NIH award 5U01AI155354-04 FY2024: $942,943 awarded for that fiscal year; activity U01 (OTHER_NIH); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Development of Non-Human Primate Models source ↗
- NIH award 5R44AI149927-04 FY2024: $998,971 awarded for that fiscal year; activity R44 (SBIR); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. A genetically modified Plasmodium falciparum sporo source ↗
- NIH award 5R43AI174393-02 FY2024: $299,951 awarded for that fiscal year; activity R43 (SBIR); PI BILLINGSLEY, PETER F.; recipient as written: SANARIA, INC., ROCKVILLE, MD. Conditional male lethal Anopheles stephensi source ↗
- NIH award 1R43AI179439-01 FY2023: $282,240 awarded for that fiscal year; activity R43 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Modularizing manufacture of PfSPZ vaccines: o source ↗
- NIH award 5R44AI125009-05 FY2023: $968,151 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. A glycolipid adjuvant to promote dose sparing source ↗
- NIH award 5R43AI172657-02 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. In vitro bioreactor production of a genetically mo source ↗
- NIH award 5R44AI134500-06 FY2023: $957,878 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Automating mosquito microdissection for a mal source ↗
- NIH award 1SB1AI174403-01 FY2023: $999,921 awarded for that fiscal year; activity SB1 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Progressing PfSPZ vaccines for malaria to lic source ↗
- NIH award 5U01AI155356-03 FY2023: $1,243,700 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. Expanding the breadth, magnitude, and durab source ↗
- NIH award 5R44AI138943-05 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BILLINGSLEY, PETER F.; recipient as written: SANARIA, INC., ROCKVILLE, MD. A Unique Automated Bioreactor for Rearing source ↗
- NIH award 5U01AI155354-03 FY2023: $942,943 awarded for that fiscal year; activity U01 (OTHER_NIH); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Development of Non-Human Primate Models source ↗
- NIH award 2R44AI149927-03 FY2023: $999,880 awarded for that fiscal year; activity R44 (SBIR); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. A genetically modified Plasmodium falciparum sporo source ↗
- NIH award 1R43AI174393-01 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI BILLINGSLEY, PETER F.; recipient as written: SANARIA, INC., ROCKVILLE, MD. Conditional male lethal Anopheles stephensi source ↗
- NIH award 1U44AI167783-01 FY2022: $988,772 awarded for that fiscal year; activity U44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. PfSPZ Vaccine for Prevention of Plasmodium fa source ↗
- NIH award 2R44AI125009-04A1 FY2022: $999,306 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. A glycolipid adjuvant to promote dose spari source ↗
- NIH award 5SB1AI058375-14 FY2022: $974,007 awarded for that fiscal year; activity SB1 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. PfSPZ Vaccine for Malaria: Towards a Successf source ↗
- NIH award 1R43AI172657-01 FY2022: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. In vitro bioreactor production of a genetically mo source ↗
- NIH award 5R44AI085740-08 FY2022: $947,054 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. In-Vitro Culture of Plasmodium falciparum Spo source ↗
- NIH award 5R44AI124867-05 FY2022: $961,340 awarded for that fiscal year; activity R44 (SBIR); PI CHAKRAVARTY, SUMANA; recipient as written: SANARIA, INC., ROCKVILLE, MD. Manufacture of aseptic, purified, cryopreserve source ↗
- NIH award 5R44AI134500-05 FY2022: $966,428 awarded for that fiscal year; activity R44 (SBIR); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Automating mosquito microdissection for a mal source ↗
- NIH award 5U01AI155356-02 FY2022: $1,279,157 awarded for that fiscal year; activity U01 (OTHER_NIH); PI SIM, B. KIM LEE; recipient as written: SANARIA, INC., ROCKVILLE, MD. Expanding the breadth, magnitude, and durab source ↗
- NIH award 5U01AI155354-02 FY2022: $942,943 awarded for that fiscal year; activity U01 (OTHER_NIH); PI HOFFMAN, STEPHEN LEV; recipient as written: SANARIA, INC., ROCKVILLE, MD. Development of Non-Human Primate Models source ↗
- NIH award 5R44AI138943-04 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BILLINGSLEY, PETER F.; recipient as written: SANARIA, INC., ROCKVILLE, MD. A Unique Automated Bioreactor for Rearing source ↗
- NIH award 5R43AI157532-02 FY2022: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI JAMES, ERIC ROBERT; recipient as written: SANARIA, INC., ROCKVILLE, MD. Attenuation of Liquid Formulation for PfSPZ Vac source ↗
- NIH award 5R44AI088853-08 FY2022: $966,818 awarded for that fiscal year; activity R44 (SBIR); PI BILLINGSLEY, PETER F.; recipient as written: SANARIA, INC., ROCKVILLE, MD. Cryopreservation of Anopheles Embryos source ↗